Related Experiment Video

Updated: Jun 17, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Targeting the checkpoint kinase Chk1 in cancer therapy

Callie Merry1, Kang Fu, Jingna Wang

  • 1Department of Pharmacology, Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Cell Cycle (Georgetown, Tex.)
|December 22, 2009
PubMed

Insights

The F-box protein Fbx6 mediates the degradation of the cell cycle kinase Chk1 during replication stress. Reduced Fbx6 levels impair Chk1 degradation, leading to cancer cell resistance to therapies.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Eukaryotic cell division relies on replication checkpoints to ensure accurate DNA duplication despite cellular insults.
  • The ATR-Chk1 pathway is crucial for delaying cell cycle progression and maintaining fork viability during replication stress.
  • Replicative stress can activate Chk1 and also trigger its ubiquitin-dependent degradation.

Purpose of the Study:

  • To identify the mediator of Chk1 ubiquitination and degradation.
  • To investigate the role of Fbx6 in regulating Chk1 levels during normal cell cycling and replication stress.
  • To explore the implications of Chk1 degradation defects in cancer cell sensitivity to therapies.

Main Methods:

  • Identification of F-box protein Fbx6 as the regulator of Chk1 ubiquitination and degradation.
  • Analysis of Chk1 and Fbx6 expression levels in cultured cancer cell lines and breast tumor tissues.
  • Assessment of tumor cell sensitivity to anticancer treatment in relation to Chk1 degradation.

Main Results:

  • Fbx6 was identified as the F-box protein responsible for Chk1 ubiquitination and degradation.
  • An inverse correlation was observed between Chk1 and Fbx6 expression in cancer cells and tumor tissues.
  • Defects in Chk1 degradation, linked to reduced Fbx6 expression, conferred resistance to anticancer treatments.

Conclusions:

  • Fbx6 plays a critical role in regulating Chk1 stability within the replication checkpoint pathway.
  • The inverse relationship between Chk1 and Fbx6 has significant implications for understanding cancer therapy resistance.
  • Targeting Fbx6-mediated Chk1 degradation may offer novel strategies to enhance cancer treatment efficacy.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...